These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 15585492)

  • 1. Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma.
    Postema EJ
    J Nucl Med; 2004 Dec; 45(12):2126-7; author reply 2127. PubMed ID: 15585492
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioimmunotherapy of Non-Hodgkin's lymphoma.
    Britton KE
    J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
    [No Abstract]   [Full Text] [Related]  

  • 3. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
    Goldenberg DM; Sharkey RM
    J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical and clinical benefits of radioimmunotherapy lead to advantages in cost-effectiveness in the treatment of patients with non-Hodgkin's lymphoma.
    Otte A; Thompson SL
    Nucl Med Commun; 2006 Oct; 27(10):753-6. PubMed ID: 16969255
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
    Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA
    Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924
    [No Abstract]   [Full Text] [Related]  

  • 7. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Friedberg JW
    Clin Cancer Res; 2004 Dec; 10(23):7789-91. PubMed ID: 15585609
    [No Abstract]   [Full Text] [Related]  

  • 8. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
    Postema EJ; Oyen WJ; Boerman OC; Corstens FH
    J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
    [No Abstract]   [Full Text] [Related]  

  • 9. Underestimation of absorbed dose to kidney.
    Postema EJ; Buijs WC; Boerman OC; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1707-8. PubMed ID: 14530491
    [No Abstract]   [Full Text] [Related]  

  • 10. Radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Whelton S
    Nurse Pract; 2007 Dec; 32(12):35-8. PubMed ID: 18043410
    [No Abstract]   [Full Text] [Related]  

  • 11. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.
    White CA; Wiseman G
    J Nucl Med; 1999 Nov; 40(11):1967-8. PubMed ID: 10565795
    [No Abstract]   [Full Text] [Related]  

  • 12. Does health economics have an impact on non-Hodgkin's lymphoma patients' options?
    Otte A
    Nucl Med Commun; 2008 Aug; 29(8):748-9. PubMed ID: 18753830
    [No Abstract]   [Full Text] [Related]  

  • 13. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
    Otte A; Dierckx RA
    Nucl Med Commun; 2005 Dec; 26(12):1045-7. PubMed ID: 16264349
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of anthropomorphic hand phantoms for personal dosimetry in 90Y-Zevalin preparation and patient delivering.
    Ciolini R; d'Errico F; Traino AC; Paternostro E; Laganà A; Romei C; Pazzagli F; Del Gratta A
    Radiat Prot Dosimetry; 2014 Jan; 158(2):216-20. PubMed ID: 23960242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma.
    Eary JF; Krohn KA; Press OW; Durack L; Bernstein ID
    Nucl Med Biol; 1997 Oct; 24(7):635-8. PubMed ID: 9352534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New directions in radioimmunotherapy of non-Hodgkin's lymphoma.
    DeNardo GL
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S4. PubMed ID: 15498148
    [No Abstract]   [Full Text] [Related]  

  • 18. Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2000 Jul; 14(7):1009, 1039. PubMed ID: 10929588
    [No Abstract]   [Full Text] [Related]  

  • 19. Commentary: let the tail wag the dog: the case for radioimmunotherapy of low-grade follicular lymphoma.
    Plastaras JP; Glatstein E; Schuster SJ
    Oncologist; 2008 Jun; 13(6):655-6. PubMed ID: 18586920
    [No Abstract]   [Full Text] [Related]  

  • 20. Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: best of both worlds?
    Boerman OC; Oyen WJ; Corstens FH
    Cancer Biother Radiopharm; 2000 Feb; 15(1):1-5. PubMed ID: 10740647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.